for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Valneva SE

VLS.PA

Latest Trade

5.71EUR

Change

-0.14(-2.39%)

Volume

441,582

Today's Range

5.64

 - 

5.99

52 Week Range

1.78

 - 

5.99

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Valneva H1 Net Loss Widens To 25.6 Million Euros

Aug 4 (Reuters) - Valneva SE <VLS.PA>::VALNEVA REPORTS H1 RESULTS MARKED BY MAJOR CORPORATE ACHIEVEMENTS AND STRONG CASH POSITION.UNPRECEDENTED PARTNERING DEAL SIGNED WITH PFIZER FOR LYME DISEASE VACCINE.BINDING PRELIMINARY AGREEMENT NOW IN PLACE WITH UK GOVERNMENT TO PROVIDE INITIAL FUNDING FOR MANUFACTURING EXPANSION OF SARS-COV-2 VACCINE.AGREEMENT IN PRINCIPLE TO SUPPLY UP TO 100 MILLION DOSES TO UK GOVERNMENT.POSITIVE INITIAL RESULTS FOR PHASE 2 STUDY OF LYME DISEASE VACCINE VLA15.POSITIVE END-OF-PHASE 2 CHIKUNGUNYA MEETING WITH THE U.S. FDA.MARKETING AND DISTRIBUTION PARTNERSHIP WITH BAVARIAN NORDIC.$85 MILLION FINANCING ARRANGEMENT WITH LEADING US HEALTHCARE FUNDS.STRONG CASH POSITION OF €200 MILLION AT END OF JUNE 2020.TOTAL REVENUES OF €47.9 MILLION IN H1 2020 COMPARED TO €54.5 MILLION IN H1 2019.H1 EBITDA LOSS OF €17.2 MILLION COMPARED TO AN EBITDA PROFIT OF €2.4 MILLION IN H1 2019.VALNEVA FY 2020 TOTAL REVENUE GUIDANCE CONFIRMED WITH MAJOR EBITDA IMPROVEMENT COMPARED TO ORIGINAL GUIDANCE.FORECASTS TOTAL 2020 REVENUES OF €120 MILLION TO €140 MILLION, BROADLY IN LINE WITH ITS ORIGINAL GUIDANCE.NOW ESTIMATES EBITDA OF BETWEEN ZERO AND NEGATIVE €10 MILLION IN 2020 (COMPARED TO ORIGINAL GUIDANCE OF UP TO €35 MILLION NEGATIVE EBITDA).IN VALNEVA GENERATED A NET LOSS AMOUNTING TO €25.6 MILLION COMPARED TO A NET LOSS OF €2.4 MILLION IN THE FIRST HALF OF 2019.

Valneva Announces Positive Initial Results For Study Of Lyme Vaccine

July 22 (Reuters) - VALVENA SE <VLS.PA>::ANNOUNCES POSITIVE INITIAL RESULTS FOR PHASE 2 STUDY OF LYME DISEASE VACCINE CANDIDATE.PHASE 2 STUDY VLA15-201 MET ITS ENDPOINTS.VLA15 GENERALLY SAFE ACROSS ALL DOSE AND AGE GROUPS TESTED.NO RELATED SERIOUS ADVERSE EVENTS (SAES) ASSOCIATED WITH VLA15.ENCOURAGING IMMUNOGENICITY PROFILE CONFIRMED, INCLUDING OLDER ADULTS (50-65 YEARS).VALNEVA EXPECTS TO REPORT TOP-LINE RESULTS FOR SECOND PHASE 2 STUDY, VLA15-202, IN A FEW MONTHS.COMPARED TO PHASE 1, HIGHER DOSES USED IN THIS TRIAL ELICITED HIGHER ANTIBODY RESPONSES ACROSS ALL SEROTYPES.

Bavarian Nordic And Valneva Announce Partnership

June 18 (Reuters) - Bavarian Nordic A/S <BAVA.CO>::REG-BAVARIAN NORDIC AND VALNEVA ANNOUNCE MARKETING AND DISTRIBUTION PARTNERSHIP.COMPANIES HAVE SIGNED A TERM SHEET OUTLINING A MUTUAL AGREEMENT, WHICH WILL CREATE SIGNIFICANT COMMERCIAL SYNERGIES AND A MARKET LEADERSHIP POSITION IN SPECIALTY VACCINE INDUSTRY.PARTNERSHIP AGREEMENT HAS NO MATERIAL SHORT TERM FINANCIAL IMPACT.WILL TRANSFER MARKETING AND DISTRIBUTION FOR RABIPUR/RABAVERT AND ENCEPUR FROM GSK FOR KEY MARKETS LATER THIS YEAR.VALNEVA TO ASSUME RESPONSIBILITY FOR MARKETING AND DISTRIBUTION OF VACCINES FOR RABIES AND TICK-BORNE ENCEPHALITIS IN SELECTED EUROPEAN COUNTRIES AND CANADA.VALNEVA TO ASSUME RESPONSIBILITY FOR MARKETING AND DISTRIBUTION OF VACCINES FOR RABIES AND TICK-BORNE ENCEPHALITIS STARTING IN H2 2020.

Valneva Partners With Batavia Biosciences For Polio Vaccine

June 15 (Reuters) - VALNEVA SE <VLS.PA>::BATAVIA BIOSCIENCES AND VALNEVA COLLABORATE TO ACCELERATE DEVELOPMENT OF LOW-COST INACTIVATED POLIO VACCINE.VALNEVA WILL RECEIVE AN UPFRONT PAYMENT AND MONTHLY SERVICE FEES.TO MANUFACTURE SIPV VACCINE FOR CLINICAL TRIAL PURPOSES IN ITS STATE-OF--ART GMP POLIO MANUFACTURING FACILITY OPERATED UNDER GAPIII POLIO CONTAINMENT.BATAVIA WILL REMAIN RESPONSIBLE FOR RELEASE AND SUPPLY OF GMP VACCINE TO DCVMS.

Valneva: Hart-Scott-Rodino Clearance For Lyme Vaccine Collaboration With Pfizer

June 8 (Reuters) - VALNEVA SE <VLS.PA>::VALNEVA ANNOUNCES HART-SCOTT-RODINO CLEARANCE FOR LYME VACCINE COLLABORATION WITH PFIZER.AGREEMENT IS NOW EFFECTIVE AND VALNEVA WILL RECEIVE A $130 MILLION UPFRONT PAYMENT..ANTITRUST-RELATED CONDITION PRECEDENT FOR LYME VACCINE COLLABORATION AGREEMENT WITH PFIZER HAS BEEN MET.VALNEVA IS ELIGIBLE TO RECEIVE A TOTAL OF $308 MILLION CASH PAYMENTS.PAYMENTS CONSISTING OF $130 MILLION UPFRONT PAYMENT DESCRIBED ABOVE, $35 MILLION IN DEVELOPMENT MILESTONES AND $143 MILLION IN EARLY COMMERCIALIZATION MILESTONES.VALNEVA WILL FUND 30% OF ALL DEVELOPMENT COSTS THROUGH COMPLETION OF DEVELOPMENT PROGRAM.IN RETURN PFIZER WILL PAY VALNEVA TIERED ROYALTIES STARTING AT 19%.

Valneva Confirms Repurchase Of About 18 Million Preferred Shares

May 29 (Reuters) - VALNEVA SE <VLS.PA>::VALNEVA CONFIRMS REPURCHASE OF PREFERRED SHARES IN ACCORDANCE WITH COMPANY'S ARTICLES.COMPANY ANNOUNCES IT WILL REPURCHASE ALL OF 17,836,719 PREFERRED SHARES AT THEIR NOMINAL VALUE OF ONE EURO CENT PER SHARE.HOLDERS DO NOT NEED TO TAKE ANY ACTION; PROCESS WILL BE IMPLEMENTED AUTOMATICALLY BY JUNE 10, 2020.IN ACCORDANCE WITH PARAGRAPH 5 IN SECTION 13.3 OF COMPANY'S ARTICLES, REPURCHASED SHARES WILL BE CANCELED AND COMPANY'S SHARE CAPITAL WILL BE REDUCED BY EUR 178,367.19.

Valneva Q1 EBITDA Down At 2.4 Million Euros

May 7 (Reuters) - Valneva SE <VLS.PA>::EBITDA OF €2.4 MILLION IN Q1 2020, LOWER THAN Q1 2019 (€8.2 MILLION) DUE TO INCREASED RESEARCH AND DEVELOPMENT INVESTMENTS.PRODUCT SALES REVENUE OF EUR 32.7 MILLION IN Q1 2020, SIMILAR TO Q1 2019 (EUR 32.8 MILLION).POSITIVE OPERATING CASH FLOW OF EUR 3.0 MILLION IN Q1 2020.STRONG CASH POSITION OF EUR 80.8 MILLION AT END OF MARCH 2020.LIMITED BUSINESS IMPACT OF COVID-19 CRISIS DURING Q1.TOTAL REVENUES NOW ESTIMATED TO BE BETWEEN EUR 95 MILLION AND EUR 135 MILLION IN 2020.PRODUCT SALES REVENUE GUIDANCE REVISED TO EUR 75 MILLION TO EUR 95 MILLION NOTING CONTINUING IMPACT OF COVID-19 PANDEMIC.EXPECTS IMPROVED NEGATIVE EBITDA OF EUR 10 MILLION TO EUR 30 MILLION IN 2020 (COMPARED TO PREVIOUS GUIDANCE OF UP TO EUR 50 MILLION NEGATIVE EBITDA) IN 2020.

Valneva To Partner With Instituto Butantan On Single-Shot Chikungunya Vaccine

May 5 (Reuters) - Valneva SE <VLS.PA>::REG-VALNEVA TO PARTNER WITH INSTITUTO BUTANTAN ON SINGLE-SHOT CHIKUNGUNYA VACCINE FOR LOW- AND MIDDLE- INCOME COUNTRIES.DEFINITIVE AGREEMENTS ARE EXPECTED TO BE FINALIZED IN NEXT SIX MONTHS.COLLABORATION FALLS WITHIN FRAMEWORK OF $23.4 MILLION IN FUNDING VALNEVA RECEIVED FROM COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS (CEPI) IN JULY 2019.

Valneva And Dynavax Announce Collaboration To Advance Vaccine Development For Covid-19

April 22 (Reuters) - Dynavax Technologies Corp <DVAX.O>::VALNEVA AND DYNAVAX ANNOUNCE COLLABORATION TO ADVANCE VACCINE DEVELOPMENT FOR COVID-19.VALNEVA SE - DYNAVAX IS PROVIDING CPG 1018 TO SUPPORT DEVELOPMENT OF VALNEVA'S COVID-19 VACCINE CANDIDATE.VALNEVA SE - VALNEVA WILL SEEK GRANT FUNDING TO SUPPORT REQUIRED INVESTMENT FOR PROGRAM.VALNEVA SE - CO, DYNAVAX WILL WORK WITH REGULATORY AUTHORITIES TO ALIGN ON OPTIMAL STRATEGY TO EXECUTE AN EXPEDITED CLINICAL DEVELOPMENT PATH.VALNEVA SE - VALNEVA AND DYNAVAX WILL WORK WITH REGULATORY AUTHORITIES WITH GOAL TO INITIATE CLINICAL TRIALS BEFORE END OF 2020.

Valneva Reports Positive End-Of-Phase 2 Chikungunya Meeting With The U.S. FDA

March 25 (Reuters) - Valneva SE <VLS.PA>::VALNEVA REPORTS POSITIVE END-OF-PHASE 2 CHIKUNGUNYA MEETING WITH THE U.S. FDA; SETS STAGE FOR PHASE 3 STUDY.STUDY INITIATION AS SOON AS COVID-19 SITUATION PERMITS, CURRENTLY ANTICIPATED FOR Q4 2020.PRIMARY ENDPOINT ANALYSIS IS EXPECTED SIX MONTHS THEREAFTER.FINAL ANALYSIS WILL BE CONDUCTED AT DAY 180 (SIX MONTHS AFTER IMMUNIZATION).TOTAL DURATION OF STUDY IS EXPECTED TO BE NINE MONTHS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up